Overview
Wave Life Sciences Q3 revenue and net income missed analyst expectations
Company maintains strong cash position, extending runway into Q2 2027
WVE-007 and WVE-006 clinical programs advance, achieving key objectives
Outlook
Wave expects multiple clinical data updates from INLIGHT trial in 2025 and 2026
Company plans to file NDA for WVE-N531 in 2026
Wave plans IND application for WVE-003 Phase 2/3 study in 2H 2025
Result Drivers
R&D - Expenses were $45.9 million in the third quarter of 2025 as compared to $41.2 million in the same period in 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $7.61 mln | $11.13 mln (15 Analysts) |
Q3 EPS | -$0.32 | ||
Q3 Net Income | Miss | -$53.85 mln | -$49.55 mln (14 Analysts) |
Q3 Income from Operations | Miss | -$56.35 mln | -$51.47 mln (14 Analysts) |
Q3 Pretax Profit | Miss | -$53.85 mln | -$49.19 mln (13 Analysts) |
Q3 Operating Expenses | $63.96 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for WAVE Life Sciences Ltd is $19.00, about 58.6% above its November 7 closing price of $7.86
Press Release: ID:nGNX9pl0nC
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments